Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,845,440
  • Shares Outstanding, K 1,770,530
  • Annual Sales, $ 31,904 M
  • Annual Income, $ 3,687 M
  • 60-Month Beta 0.92
  • Price/Sales 6.08
  • Price/Cash Flow 21.94
  • Price/Book 6.29
Trade ABT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.36
  • Number of Estimates 9
  • High Estimate 1.40
  • Low Estimate 1.34
  • Prior Year 0.95
  • Growth Rate Est. (year over year) +43.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.82 +3.06%
on 09/28/20
111.57 -4.10%
on 10/12/20
+3.55 (+3.43%)
since 09/25/20
3-Month
98.41 +8.73%
on 07/27/20
114.19 -6.30%
on 08/28/20
+8.05 (+8.14%)
since 07/24/20
52-Week
61.61 +73.67%
on 03/23/20
114.19 -6.30%
on 08/28/20
+25.35 (+31.05%)
since 10/25/19

Most Recent Stories

More News
Global Autoimmune Diseases Diagnostics Market Report 2020-2025 with Profiles of Abbott Laboratories, Siemens AG, Beckman Coulter Inc. and Quest Diagnostics

The "Global Autoimmune Diseases Diagnostics Market 2020-2025 by Product, Test Type, Disease, End-user, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's...

ABT : 107.00 (-0.73%)
SIEGY : 71.7100 (+1.85%)
Varicella Zoster Infection Treatment Market Research Report by Product, by Material, by Gender, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it...

ABT : 107.00 (-0.73%)
GSK : 35.40 (+0.31%)
NVS : 84.00 (-0.51%)
PFE : 37.95 (-0.60%)
TEVA : 9.31 (-0.43%)
VRX.TO : 30.80 (-3.33%)
3 Top Stocks That Will Outperform Whether Trump is Reelected or Not

The market (SPY) appears to be on a track of continued volatility, until at least after the election. That could mean uncertainty for your portfolio, unless you invest in stocks that would benefit from...

SPY : 341.74 (-1.17%)
LMT : 370.00 (-1.16%)
URI : 186.08 (-1.15%)
ABT : 107.00 (-0.73%)
Surging Earnings Estimates Signal Upside for Abbott (ABT) Stock

Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

ABT : 107.00 (-0.73%)
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark

BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.

BDX : 240.28 (-0.34%)
DGX : 126.94 (-0.15%)
ABT : 107.00 (-0.73%)
FLDM : 6.45 (unch)
OPKO Health's (OPK) BioReference Laboratories Unveils New Test

OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.

BDX : 240.28 (-0.34%)
DGX : 126.94 (-0.15%)
ABT : 107.00 (-0.73%)
OPK : 4.22 (-1.86%)
Diagnostic Testing Capabilities Improve in the Face of Global Turmoil

, /PRNewswire/ -- While biotech companies work on vaccines and possible treatments and medical device companies focus on patient monitoring solutions, many others have been working on improving testing...

TOMDF : 0.0580 (-10.77%)
ADIL : 1.7600 (-2.22%)
PFE : 37.95 (-0.60%)
JNJ : 145.20 (-0.03%)
ABT : 107.00 (-0.73%)
Worldwide Neurovascular Intervention Devices Industry to 2027 - Abbott Laboratories, Balt Extrusion & Boston Scientific Among Others

The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

ABT : 107.00 (-0.73%)
BSX : 36.85 (-0.86%)
Prosthetic Heart Valve Market Research Report by Type, by Offering, by Communication Protocol, by Industry - Global Forecast to 2025 - Cumulative Impact of COVID-19

The Global is expected to exceed more than USD$ 4 Billion by 2024; Growing at a CAGR of more than 9% in the given forecast period.

ABT : 107.00 (-0.73%)
BSX : 36.85 (-0.86%)
CRY : 19.34 (+1.31%)
EW : 79.50 (-1.13%)
LIFE : 3.48 (+5.14%)
NVCN.TO : 2.66 (-13.07%)
STJ : 80.82 (+0.16%)
Global Cryptococcosis Treatment Market 2020-2025 - Key Players are Glenmark Pharmaceuticals, Abbott Laboratories, Pfizer, Bristol-Mayers Squibb, Sigmapharm Laboratories, Novartis

The "Global Cryptococcosis Treatment Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.

ABT : 107.00 (-0.73%)
NVS : 84.00 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Key Turning Points

2nd Resistance Point 110.88
1st Resistance Point 109.34
Last Price 107.00
1st Support Level 106.91
2nd Support Level 106.02

See More

52-Week High 114.19
Last Price 107.00
Fibonacci 61.8% 94.11
Fibonacci 50% 87.90
Fibonacci 38.2% 81.70
52-Week Low 61.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar